| Dr Robert Floyd Nuss, MD | |
|
4400 W. 69th St., Ste. 1500, Sioux Falls, SD 57108-8171 | |
| (605) 322-5700 | |
| Not Available |
| Full Name | Dr Robert Floyd Nuss |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 14 Years |
| Location | 4400 W. 69th St., Sioux Falls, South Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013295682 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Avera Mckennan Hospital & University Health Center | Sioux falls, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Avera Mckennan | 0345157103 | 848 |
| Southeastern Behavioral Healthcare | 7618867367 | 7 |
News Archive
Compass Clinical Consulting (http://www.compass-clinical.com) launched a new resource-rich, Web 2.0 website today: HOSPITALS 2.0
According to federal advisors last Thursday, obesity drugs should undergo clinical trials to ensure that they do not cause heart attacks. This would make it harder for these drugs to receive approval.
The Associated Press/Seattle Times reports on a "mysterious epidemic that is devastating the Pacific Coast of Central America, killing more than 24,000 people in El Salvador and Nicaragua since 2000 and striking thousands of others with chronic kidney disease at rates unseen virtually anywhere else."
PAREXEL Consulting, a business unit of PAREXEL International and leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released two new white papers from leading biosimilar experts that provide key insights into emerging areas of biosimilar development.
Two papers to be published in the Early Edition online of the Proceedings of the National Academy of Sciences (PNAS) the week of July 30-August 3, 2007 report findings that demonstrate that neuroprotectin D1 (NPD1) protects against damage to retinal pigment epithelial (RPE) cells and identifies an important trigger for its production and novel molecular mechanisms that support vision.
› Verified 2 days ago
| Entity Name | Avera Mckennan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003389206 PECOS PAC ID: 0345157103 Enrollment ID: O20031110000117 |
News Archive
Compass Clinical Consulting (http://www.compass-clinical.com) launched a new resource-rich, Web 2.0 website today: HOSPITALS 2.0
According to federal advisors last Thursday, obesity drugs should undergo clinical trials to ensure that they do not cause heart attacks. This would make it harder for these drugs to receive approval.
The Associated Press/Seattle Times reports on a "mysterious epidemic that is devastating the Pacific Coast of Central America, killing more than 24,000 people in El Salvador and Nicaragua since 2000 and striking thousands of others with chronic kidney disease at rates unseen virtually anywhere else."
PAREXEL Consulting, a business unit of PAREXEL International and leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released two new white papers from leading biosimilar experts that provide key insights into emerging areas of biosimilar development.
Two papers to be published in the Early Edition online of the Proceedings of the National Academy of Sciences (PNAS) the week of July 30-August 3, 2007 report findings that demonstrate that neuroprotectin D1 (NPD1) protects against damage to retinal pigment epithelial (RPE) cells and identifies an important trigger for its production and novel molecular mechanisms that support vision.
› Verified 2 days ago
| Entity Name | Southeastern Behavioral Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114002573 PECOS PAC ID: 7618867367 Enrollment ID: O20040317000821 |
News Archive
Compass Clinical Consulting (http://www.compass-clinical.com) launched a new resource-rich, Web 2.0 website today: HOSPITALS 2.0
According to federal advisors last Thursday, obesity drugs should undergo clinical trials to ensure that they do not cause heart attacks. This would make it harder for these drugs to receive approval.
The Associated Press/Seattle Times reports on a "mysterious epidemic that is devastating the Pacific Coast of Central America, killing more than 24,000 people in El Salvador and Nicaragua since 2000 and striking thousands of others with chronic kidney disease at rates unseen virtually anywhere else."
PAREXEL Consulting, a business unit of PAREXEL International and leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released two new white papers from leading biosimilar experts that provide key insights into emerging areas of biosimilar development.
Two papers to be published in the Early Edition online of the Proceedings of the National Academy of Sciences (PNAS) the week of July 30-August 3, 2007 report findings that demonstrate that neuroprotectin D1 (NPD1) protects against damage to retinal pigment epithelial (RPE) cells and identifies an important trigger for its production and novel molecular mechanisms that support vision.
› Verified 2 days ago
| Entity Name | Monument Health Rapid City Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275553463 PECOS PAC ID: 6002729506 Enrollment ID: O20070625000144 |
News Archive
Compass Clinical Consulting (http://www.compass-clinical.com) launched a new resource-rich, Web 2.0 website today: HOSPITALS 2.0
According to federal advisors last Thursday, obesity drugs should undergo clinical trials to ensure that they do not cause heart attacks. This would make it harder for these drugs to receive approval.
The Associated Press/Seattle Times reports on a "mysterious epidemic that is devastating the Pacific Coast of Central America, killing more than 24,000 people in El Salvador and Nicaragua since 2000 and striking thousands of others with chronic kidney disease at rates unseen virtually anywhere else."
PAREXEL Consulting, a business unit of PAREXEL International and leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released two new white papers from leading biosimilar experts that provide key insights into emerging areas of biosimilar development.
Two papers to be published in the Early Edition online of the Proceedings of the National Academy of Sciences (PNAS) the week of July 30-August 3, 2007 report findings that demonstrate that neuroprotectin D1 (NPD1) protects against damage to retinal pigment epithelial (RPE) cells and identifies an important trigger for its production and novel molecular mechanisms that support vision.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Floyd Nuss, MD 4400 W. 69th St., Ste. 1500, Sioux Falls, SD 57108-8171 Ph: (605) 322-5700 | Dr Robert Floyd Nuss, MD 4400 W. 69th St., Ste. 1500, Sioux Falls, SD 57108-8171 Ph: (605) 322-5700 |
News Archive
Compass Clinical Consulting (http://www.compass-clinical.com) launched a new resource-rich, Web 2.0 website today: HOSPITALS 2.0
According to federal advisors last Thursday, obesity drugs should undergo clinical trials to ensure that they do not cause heart attacks. This would make it harder for these drugs to receive approval.
The Associated Press/Seattle Times reports on a "mysterious epidemic that is devastating the Pacific Coast of Central America, killing more than 24,000 people in El Salvador and Nicaragua since 2000 and striking thousands of others with chronic kidney disease at rates unseen virtually anywhere else."
PAREXEL Consulting, a business unit of PAREXEL International and leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released two new white papers from leading biosimilar experts that provide key insights into emerging areas of biosimilar development.
Two papers to be published in the Early Edition online of the Proceedings of the National Academy of Sciences (PNAS) the week of July 30-August 3, 2007 report findings that demonstrate that neuroprotectin D1 (NPD1) protects against damage to retinal pigment epithelial (RPE) cells and identifies an important trigger for its production and novel molecular mechanisms that support vision.
› Verified 2 days ago
Dr. Alex James Linn, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1301 S Cliff Ave Ste 610, Sioux Falls, SD 57105 Phone: 605-322-8860 Fax: 605-322-8868 | |
Amber Olson, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4400 W 69th St, Sioux Falls, SD 57108 Phone: 605-322-4005 | |
Sarah A Flynn, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4400 W 69th St, Ste 1500, Sioux Falls, SD 57108 Phone: 605-322-5700 Fax: 605-322-5704 | |
Mackenzie Mertz, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2400 W 49th St, Sioux Falls, SD 57105 Phone: 605-312-8700 | |
Georgiana Nuss, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2400 W 49th St, Sioux Falls, SD 57105 Phone: 605-312-8700 | |
Hannah Statz Devries, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4400 W 69th St Ste 1500, Sioux Falls, SD 57108 Phone: 605-322-5700 |